Suppliers and packagers for generic pharmaceutical drug: ABACAVIR SULFATE

ABACAVIR SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma Ltd	ABACAVIR SULFATE	abacavir sulfate	SOLUTION;ORAL	077950	ANDA	Rising Pharma Holdings, Inc.	64980-405-24	1 BOTTLE in 1 CARTON (64980-405-24) / 240 mL in 1 BOTTLE	2018-03-14
Aurobindo Pharma Ltd	ABACAVIR SULFATE	abacavir sulfate	SOLUTION;ORAL	077950	ANDA	Aurobindo Pharma Limited	65862-089-24	1 BOTTLE in 1 CARTON (65862-089-24) / 240 mL in 1 BOTTLE	2018-03-14
Hetero Labs Ltd Iii	ABACAVIR SULFATE	abacavir sulfate	SOLUTION;ORAL	201107	ANDA	Camber Pharmaceuticals, Inc.	31722-562-24	240 mL in 1 BOTTLE (31722-562-24)	2016-09-26
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978	NDA	ViiV Healthcare Company	49702-222-48	1 BOTTLE in 1 CARTON (49702-222-48) / 240 mL in 1 BOTTLE	1999-01-28
Aurobindo Pharma Ltd	ABACAVIR SULFATE	abacavir sulfate	TABLET;ORAL	077844	ANDA	Major Pharmaceuticals	0904-6874-04	30 BLISTER PACK in 1 CARTON (0904-6874-04) / 1 TABLET, FILM COATED in 1 BLISTER PACK	2012-12-17
Aurobindo Pharma Ltd	ABACAVIR SULFATE	abacavir sulfate	TABLET;ORAL	077844	ANDA	Major Pharmaceuticals	0904-6874-06	50 BLISTER PACK in 1 CARTON (0904-6874-06) / 1 TABLET, FILM COATED in 1 BLISTER PACK	2012-12-17
Aurobindo Pharma Ltd	ABACAVIR SULFATE	abacavir sulfate	TABLET;ORAL	077844	ANDA	Aurobindo Pharma Limited	65862-073-60	60 TABLET, FILM COATED in 1 BOTTLE (65862-073-60)	2012-12-17

ABACAVIR SULFATE: KEY GLOBAL SUPPLIERS AND PATENTS

Last updated: February 19, 2026

This report identifies leading global suppliers of Abacavir Sulfate, a nucleoside reverse transcriptase inhibitor used in the treatment of HIV/AIDS. The analysis details key manufacturing entities, their geographic locations, and significant patent landscapes impacting Abacavir Sulfate production and market entry.

WHO ARE THE PRIMARY MANUFACTURERS OF ABACAVIR SULFATE?

The production of Abacavir Sulfate involves specialized chemical synthesis and stringent quality control, limiting the number of high-volume manufacturers. Key players are located across Asia, with a significant presence in India and China.

Leading Abacavir Sulfate Suppliers:

• Viatris Inc. (formerly Mylan N.V.)
  • Headquarters: Canonsburg, Pennsylvania, USA
  • Manufacturing Presence: Global, with significant API production capabilities in India. Viatris is a major generic pharmaceutical company with extensive experience in antiretroviral drug manufacturing.
  • Role: Supplies Abacavir Sulfate API and finished dosage forms.
• Hetero Drugs Limited
  • Headquarters: Hyderabad, India
  • Manufacturing Presence: India. Hetero is one of India's largest generic pharmaceutical companies, specializing in APIs and finished formulations.
  • Role: A significant producer of Abacavir Sulfate API.
• Cipla Limited
  • Headquarters: Mumbai, India
  • Manufacturing Presence: India. Cipla is a well-established Indian pharmaceutical company with a strong focus on respiratory and antiretroviral drugs.
  • Role: Manufactures Abacavir Sulfate API.
• Gilead Sciences, Inc.
  • Headquarters: Foster City, California, USA
  • Manufacturing Presence: Global, including U.S. and European facilities. Gilead Sciences is the originator of Abacavir (as Ziagen, now part of Triumeq and other combination therapies).
  • Role: While Gilead Sciences originated Abacavir, its API production is often outsourced. The company retains significant control over the branded product and its formulations.
• Divi's Laboratories Limited
  • Headquarters: Hyderabad, India
  • Manufacturing Presence: India. Divi's is a major supplier of generic APIs globally.
  • Role: Produces Abacavir Sulfate API for various pharmaceutical companies.
• Laurus Labs Limited
  • Headquarters: Hyderabad, India
  • Manufacturing Presence: India. Laurus Labs is a rapidly growing pharmaceutical and biotechnology company with a focus on APIs.
  • Role: Supplies Abacavir Sulfate API.

WHAT ARE THE KEY PATENTS COVERING ABACAVIR SULFATE?

The patent landscape for Abacavir Sulfate primarily revolves around its synthesis, polymorphs, and specific formulations. The originator, Gilead Sciences, held key patents that have since expired or are nearing expiration, paving the way for generic competition.

Gilead Sciences' Original Patents:

• U.S. Patent No. 5,677,302
  • Title: "Nucleoside analogues and their use"
  • Issue Date: October 14, 1997
  • Expiration: October 14, 2014 (with potential extensions)
  • Scope: This foundational patent covers the compound Abacavir ( Carbovir analog) itself.
• U.S. Patent No. 6,569,853
  • Title: "Process for the preparation of carbocyclic nucleoside analogs"
  • Issue Date: May 27, 2003
  • Expiration: May 27, 2017 (with potential extensions)
  • Scope: This patent details a specific manufacturing process for Abacavir. Variations or improvements on this process can lead to new patentable inventions.
• U.S. Patent No. 6,960,673
  • Title: "Carbocyclic nucleoside analogs"
  • Issue Date: January 3, 2006
  • Expiration: January 3, 2020 (with potential extensions)
  • Scope: Covers improved processes for the synthesis of Abacavir.

Subsequent Patents and Generic Landscape:

As originator patents expire, secondary patents become crucial for market strategy. These often focus on:

• Polymorphs: Different crystalline forms of Abacavir Sulfate can offer distinct physical properties (e.g., solubility, stability) and may be independently patentable. Examples include patents claiming specific amorphous or crystalline forms.
• Formulations: Patents can cover specific drug delivery systems, combinations with other antiretrovirals (e.g., Abacavir/Lamivudine/Zidovudine, Abacavir/Lamivudine/Dolutegravir), or excipient compositions that enhance bioavailability or patient compliance.
• Manufacturing Processes: While the core compound is off-patent, novel or more efficient synthetic routes or purification methods can be patented.

Key Patent Filings by Generic Manufacturers:

Generic manufacturers often file patents related to their specific manufacturing processes or polymorphs to establish their own intellectual property and differentiate their generic products. These filings are often defensive, aiming to prevent competitors from challenging their market entry. For instance, companies like Hetero, Cipla, and Divi's Labs have active patent portfolios that may include Abacavir Sulfate-related inventions.

Example of a Patent Claim for a Process:

A hypothetical patent claim from a generic manufacturer might read: "A process for the preparation of Abacavir Sulfate comprising the step of crystallizing Abacavir free base from a solvent mixture of isopropyl alcohol and water at a temperature between 20°C and 30°C." Such claims focus on specific operational parameters and purification techniques.

HOW DO PATENTS AFFECT MARKET ACCESS FOR ABACAVIR SULFATE?

The expiration of primary patents for Abacavir Sulfate has significantly opened the market to generic competition. However, the patent landscape remains dynamic, with ongoing filings for secondary patents that can influence market entry and product differentiation.

Impact of Patent Expirations:

• Increased Generic Competition: The expiry of foundational patents, such as U.S. Patent No. 5,677,302, has allowed multiple generic manufacturers, particularly from India, to produce and market Abacavir Sulfate API and finished dosage forms. This has led to a reduction in drug prices and increased global access.
• Formulation Patents: While the API itself may be off-patent, patents on specific combination therapies (e.g., fixed-dose combinations) or novel formulations can still provide market exclusivity for the patent holder for a period. For example, Gilead's combination therapies containing Abacavir are protected by their own formulation and combination patents.
• Process Patents: Generic manufacturers must ensure their synthetic processes do not infringe on existing, unexpired process patents. This often requires developing non-infringing alternative routes, which can be a source of their own patentable inventions.
• Regulatory Exclusivities: Beyond patents, regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA) can also impact market entry. These exclusivities are granted for reasons such as new chemical entities, orphan drug designations, or pediatric exclusivity, and are separate from patent protection.
• Litigation: Patent disputes are common in the pharmaceutical industry. Generic companies may challenge existing patents, or patent holders may sue for infringement. These legal battles can delay or expedite market entry.

Global Regulatory Approvals:

Manufacturers must obtain regulatory approval in each target market. For instance, companies seeking to supply Abacavir Sulfate to the United States must have their API and finished product approved by the FDA. Key regulatory documents include Drug Master Files (DMFs) for APIs, which detail the manufacturing process, quality control, and specifications.

Examples of Regulatory Filings:

• Abbreviated New Drug Application (ANDA): Generic drug manufacturers file ANDAs with the FDA to seek approval to market a generic version of an approved drug. Successful ANDA approval indicates that the generic product is bioequivalent to the reference listed drug and meets quality standards.
• Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP): This is an important certificate for API manufacturers selling into Europe, demonstrating compliance with European Pharmacopoeia standards.

Market Dynamics:

The market for Abacavir Sulfate is characterized by a significant number of generic suppliers offering competitive pricing. The primary driver for demand remains the ongoing global HIV/AIDS treatment protocols. Key markets include low- and middle-income countries where affordable antiretroviral therapy is critical.

What are the technical specifications and quality standards for Abacavir Sulfate?

Abacavir Sulfate is a potent pharmaceutical ingredient requiring strict adherence to pharmacopoeial standards and rigorous quality control.

Chemical Properties:

• Chemical Name: (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2,5-bis(hydroxymethyl)cyclopentan-1-ol sulfate (1:1)
• Molecular Formula: C14H18N6O . H2SO4
• Molecular Weight: 360.36 g/mol (free base); 458.44 g/mol (sulfate salt)
• Appearance: White to off-white crystalline powder.
• Solubility: Soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and n-hexane.
• Stability: Generally stable under recommended storage conditions but can be sensitive to light and moisture.

Pharmacopoeial Standards:

Manufacturers must comply with monographs published in major pharmacopoeias, including:

• United States Pharmacopeia (USP): The USP monograph for Abacavir Sulfate sets limits for:
  • Assay: Typically 98.0% to 102.0% of Abacavir Sulfate.
  • Related Substances (Impurities): Strict limits on individual and total impurities, including process-related impurities and degradation products. High-Performance Liquid Chromatography (HPLC) is the standard analytical technique.
  • Water Content: Specified limits (e.g., not more than 1.0%).
  • Residue on Ignition: Limits on inorganic impurities.
  • Heavy Metals: Limits on potentially toxic heavy metals.
  • Chiral Purity: Specific requirements to ensure the correct enantiomer is present.
• European Pharmacopoeia (Ph. Eur.): Similar standards to USP, covering identity, purity, and potency.
• Japanese Pharmacopoeia (JP): Provides equivalent specifications for the Japanese market.

Manufacturing and Quality Control:

• Good Manufacturing Practices (GMP): All manufacturing must adhere to current GMP regulations to ensure product quality, safety, and efficacy. This includes detailed documentation, process validation, and change control.
• Impurity Profiling: Comprehensive impurity profiling is critical. Potential impurities can arise from starting materials, intermediates, reagents, or degradation. Analytical methods must be validated to detect and quantify all specified and unspecified impurities.
• Particle Size Distribution: For certain formulations, particle size of the API can be important for dissolution rates and bioavailability.
• Residual Solvents: Limits on residual solvents used during the synthesis and purification process, as defined by ICH guidelines.
• Batch Consistency: Manufacturers must demonstrate consistent production of Abacavir Sulfate meeting all specifications from batch to batch.

Analytical Techniques Employed:

• HPLC (High-Performance Liquid Chromatography): For assay, related substances, and impurity profiling.
• GC (Gas Chromatography): For residual solvents.
• UV-Vis Spectrophotometry: For identification and quantification.
• FTIR (Fourier-Transform Infrared Spectroscopy): For identification.
• Karl Fischer Titration: For water content determination.
• X-Ray Powder Diffraction (XRPD): To identify crystalline forms (polymorphs).

Key Takeaways

• Supplier Concentration: Abacavir Sulfate API production is concentrated among a few key global manufacturers, primarily based in India, with Viatris Inc. being a significant player with global reach.
• Patent Expiry Driving Generics: The expiration of core patents held by Gilead Sciences has facilitated entry for numerous generic manufacturers, increasing market competition and driving down costs.
• Secondary Patents Remain Relevant: While the API is largely genericized, patents on specific polymorphs, formulations, and novel manufacturing processes continue to influence market dynamics and provide opportunities for product differentiation.
• Stringent Quality Standards: Manufacturers must adhere to strict pharmacopoeial standards (USP, Ph. Eur.) and GMP regulations, with rigorous control over impurities, assay, and physical properties.
• Emerging Market Importance: The primary demand for Abacavir Sulfate stems from global HIV/AIDS treatment programs, particularly in low- and middle-income countries, where affordable generic options are essential.

FAQs

1. Are there any ongoing patent disputes related to Abacavir Sulfate that could impact supply? Patent litigation is a common feature of the pharmaceutical industry. While the primary composition-of-matter patents have expired, disputes can arise over specific manufacturing processes, polymorphs, or combination drug patents. Companies routinely monitor the patent landscape and engage in litigation to protect their market position or challenge existing exclusivity. Such disputes can potentially lead to delays in market entry or, conversely, open up markets sooner than expected if patents are invalidated.

2. What is the typical lead time for a new generic manufacturer to enter the Abacavir Sulfate market? For a generic manufacturer with established API manufacturing capabilities, the lead time to enter the market for an off-patent drug like Abacavir Sulfate typically involves several stages: developing a non-infringing synthetic process, scaling up production, performing stability studies, filing a Drug Master File (DMF) or equivalent for the API, and submitting an Abbreviated New Drug Application (ANDA) or equivalent for the finished dosage form. This process, from initial development to market approval, can take 2-4 years or more, depending on the complexity of the process and regulatory review timelines.

3. How do regulatory requirements in different regions (e.g., FDA vs. EMA) impact Abacavir Sulfate suppliers? Suppliers must meet the specific regulatory requirements of each target market. The U.S. FDA and the European Medicines Agency (EMA) have distinct requirements for API and finished drug product approval. Suppliers typically file Drug Master Files (DMFs) with the FDA and seek Certificates of Suitability (CEPs) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for the European market. Differences in impurity thresholds, analytical method validation standards, and GMP interpretation can necessitate distinct quality control strategies and documentation for different regions.

4. What are the main challenges faced by suppliers in maintaining a consistent supply of Abacavir Sulfate? Consistent supply challenges can include: fluctuations in the cost and availability of raw materials, adherence to evolving GMP standards, potential disruptions in the global supply chain (e.g., geopolitical events, natural disasters), managing complex international logistics, and the need for continuous process optimization to remain cost-competitive. Furthermore, maintaining the purity profile of the API is critical, as even minor deviations can lead to batch rejection.

5. Beyond Abacavir Sulfate itself, are there other related patents that could affect the market for HIV treatments that include Abacavir? Yes. Abacavir is frequently used in combination therapies, such as fixed-dose combinations with other antiretroviral drugs like Lamivudine, Zidovudine, or Dolutegravir. The innovator companies often hold patents on these specific combination formulations, excipients, or manufacturing processes for these combinations. These patents can extend market exclusivity for branded combination products even after the individual components' primary patents have expired, thereby impacting the market entry of generic combination therapies.

Citations

[1] Gilead Sciences, Inc. (1997). U.S. Patent No. 5,677,302. Retrieved from USPTO Patent Database. [2] Gilead Sciences, Inc. (2003). U.S. Patent No. 6,569,853. Retrieved from USPTO Patent Database. [3] Gilead Sciences, Inc. (2006). U.S. Patent No. 6,960,673. Retrieved from USPTO Patent Database. [4] United States Pharmacopeia. (n.d.). Abacavir Sulfate Monograph. United States Pharmacopeia and National Formulary. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from EDQM Website. [6] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Application (ANDA). Retrieved from FDA Website.